94 related articles for article (PubMed ID: 7513143)
1. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.
Lenzi R; Frost P; Abbruzzese JL
Anticancer Res; 1994; 14(1A):247-51. PubMed ID: 7513143
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
Anzai H; Frost P; Abbruzzese JL
Cancer Res; 1992 Apr; 52(8):2180-5. PubMed ID: 1373105
[TBL] [Abstract][Full Text] [Related]
3. Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells.
Frost P; Abbruzzese JL; Hunt B; Lee D; Ellis M
Cancer Res; 1990 Aug; 50(15):4572-7. PubMed ID: 1695122
[TBL] [Abstract][Full Text] [Related]
4. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
6. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
7. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
8. Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.
Abbruzzese JL; Frost P
Cancer Chemother Pharmacol; 1992; 30(1):31-6. PubMed ID: 1375133
[TBL] [Abstract][Full Text] [Related]
9. The differential expression of cytokeratin 18 in cisplatin-sensitive and -resistant human ovarian adenocarcinoma cells and its association with drug sensitivity.
Parekh HK; Simpkins H
Cancer Res; 1995 Nov; 55(22):5203-6. PubMed ID: 7585575
[TBL] [Abstract][Full Text] [Related]
10. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
11. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
[TBL] [Abstract][Full Text] [Related]
12. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells.
Levasseur LM; Greco WR; Rustum YM; Slocum HK
Cancer Chemother Pharmacol; 1997; 40(6):495-505. PubMed ID: 9332464
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between cytochrome c-mediated caspase-3 activity and chemoresistance in cisplatin-resistant human ovarian cancer cell lines].
Yang X; Zheng F; Xing H; Gao Q; Wang W; Lu Y; Wang S; Ma D
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):544-7. PubMed ID: 12667321
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
15. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin.
Shang D; Liu Y; Matsui Y; Ito N; Nishiyama H; Kamoto T; Ogawa O
Urology; 2008 Jun; 71(6):1220-5. PubMed ID: 18538698
[TBL] [Abstract][Full Text] [Related]
16. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
19. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
20. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells.
Wasenius VM; Jekunen A; Monni O; Joensuu H; Aebi S; Howell SB; Knuutila S
Genes Chromosomes Cancer; 1997 Apr; 18(4):286-91. PubMed ID: 9087568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
